GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (FRA:9VC) » Definitions » Other Net Income (Loss)

ATAI Life Sciences NV (FRA:9VC) Other Net Income (Loss) : €-1.84 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV Other Net Income (Loss)?

ATAI Life Sciences NV's Other Net Income (Loss) for the three months ended in Dec. 2024 was €0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was €-1.84 Mil.

ATAI Life Sciences NV's quarterly Other Net Income (Loss) increased from Jun. 2024 (€-0.25 Mil) to Sep. 2024 (€-0.02 Mil) and increased from Sep. 2024 (€-0.02 Mil) to Dec. 2024 (€0.00 Mil).

ATAI Life Sciences NV's annual Other Net Income (Loss) increased from Dec. 2022 (€-15.11 Mil) to Dec. 2023 (€-3.29 Mil) and increased from Dec. 2023 (€-3.29 Mil) to Dec. 2024 (€-1.91 Mil).


ATAI Life Sciences NV Other Net Income (Loss) Historical Data

The historical data trend for ATAI Life Sciences NV's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV Other Net Income (Loss) Chart

ATAI Life Sciences NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Net Income (Loss)
Get a 7-Day Free Trial -62.89 -36.84 -15.11 -3.29 -1.91

ATAI Life Sciences NV Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.36 -1.57 -0.25 -0.02 -

ATAI Life Sciences NV Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ATAI Life Sciences NV Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of ATAI Life Sciences NV's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


ATAI Life Sciences NV Business Description

Traded in Other Exchanges
Address
Wallstrasse 16, Berlin, BB, DEU, 10179
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

ATAI Life Sciences NV Headlines

No Headlines